Abstract
Cancer procoagulant (CP) is a cysteine proteinase from cancer cells that initiates blood coagulation. Members of two classes of unique and highly specific cysteine proteinase inhibitors, peptidyl diazomethyl ketones (PDK) and peptidyl sulfonium salts (PSS), were studied to determine whether or not they inhibited CP. The inhibitors did not impair the activity of the coagulation system. There was a differential inhibitory effect of the 6 PDK and 2 PSS inhibitors, influenced by the amino acid composition or sequence of the peptide moiety, that suggests differences in structural features of the active site of CP and papain. CP was inhibited by both classes of inhibitors.
| Original language | English |
|---|---|
| Pages (from-to) | 389-398 |
| Number of pages | 10 |
| Journal | Thrombosis Research |
| Volume | 54 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - Jun 1 1989 |
Fingerprint
Keywords
- cancer procoagulant
- coagulation
- cysteine proteinase
- cysteine proteinase inhibitor
- peptidyl diazomethyl ketone
- peptidyl sulfonium salt
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
- Hematology
Cite this
Inhibition of cancer procoagulant by peptidyl diazomethyl ketones and peptidyl sulfonium salts. / Falanga, Anna; Shaw, Elliott; Donati, Maria Benedetta; Consonni, Rossella; Barbui, Tiziano; Gordon, Stuart.
In: Thrombosis Research, Vol. 54, No. 5, 01.06.1989, p. 389-398.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Inhibition of cancer procoagulant by peptidyl diazomethyl ketones and peptidyl sulfonium salts
AU - Falanga, Anna
AU - Shaw, Elliott
AU - Donati, Maria Benedetta
AU - Consonni, Rossella
AU - Barbui, Tiziano
AU - Gordon, Stuart
PY - 1989/6/1
Y1 - 1989/6/1
N2 - Cancer procoagulant (CP) is a cysteine proteinase from cancer cells that initiates blood coagulation. Members of two classes of unique and highly specific cysteine proteinase inhibitors, peptidyl diazomethyl ketones (PDK) and peptidyl sulfonium salts (PSS), were studied to determine whether or not they inhibited CP. The inhibitors did not impair the activity of the coagulation system. There was a differential inhibitory effect of the 6 PDK and 2 PSS inhibitors, influenced by the amino acid composition or sequence of the peptide moiety, that suggests differences in structural features of the active site of CP and papain. CP was inhibited by both classes of inhibitors.
AB - Cancer procoagulant (CP) is a cysteine proteinase from cancer cells that initiates blood coagulation. Members of two classes of unique and highly specific cysteine proteinase inhibitors, peptidyl diazomethyl ketones (PDK) and peptidyl sulfonium salts (PSS), were studied to determine whether or not they inhibited CP. The inhibitors did not impair the activity of the coagulation system. There was a differential inhibitory effect of the 6 PDK and 2 PSS inhibitors, influenced by the amino acid composition or sequence of the peptide moiety, that suggests differences in structural features of the active site of CP and papain. CP was inhibited by both classes of inhibitors.
KW - cancer procoagulant
KW - coagulation
KW - cysteine proteinase
KW - cysteine proteinase inhibitor
KW - peptidyl diazomethyl ketone
KW - peptidyl sulfonium salt
UR - http://www.scopus.com/inward/record.url?scp=0024368970&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0024368970&partnerID=8YFLogxK
U2 - 10.1016/0049-3848(89)90209-0
DO - 10.1016/0049-3848(89)90209-0
M3 - Article
C2 - 2772865
AN - SCOPUS:0024368970
VL - 54
SP - 389
EP - 398
JO - Thrombosis Research
JF - Thrombosis Research
SN - 0049-3848
IS - 5
ER -